Kiniksa Pharmaceuticals (NASDAQ:KNSA) Receives Outperform Rating from Wedbush

Kiniksa Pharmaceuticals (NASDAQ:KNSA)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a research note issued to investors on Tuesday, RTT News reports. They presently have a $30.00 price target on the stock. Wedbush’s target price would indicate a potential upside of 67.97% from the stock’s current price.

Separately, TheStreet upgraded shares of Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a research note on Thursday, February 29th.

Kiniksa Pharmaceuticals Price Performance

KNSA opened at $17.86 on Tuesday. Kiniksa Pharmaceuticals has a fifty-two week low of $10.65 and a fifty-two week high of $22.09. The firm has a market capitalization of $1.26 billion, a PE ratio of 99.23 and a beta of 0.27. The company’s 50-day moving average is $19.36 and its 200 day moving average is $18.00.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, April 23rd. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.11). The company had revenue of $79.90 million during the quarter, compared to analysts’ expectations of $76.97 million. Kiniksa Pharmaceuticals had a negative return on equity of 6.12% and a net margin of 5.11%. The business’s revenue for the quarter was up 65.4% compared to the same quarter last year. During the same period last year, the company earned ($0.18) earnings per share. As a group, analysts expect that Kiniksa Pharmaceuticals will post -0.06 EPS for the current year.

Insider Activity

In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 9,659 shares of Kiniksa Pharmaceuticals stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $21.45, for a total value of $207,185.55. Following the sale, the chief accounting officer now owns 17,588 shares of the company’s stock, valued at $377,262.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CAO Michael R. Megna sold 5,126 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total value of $111,695.54. Following the completion of the transaction, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at approximately $383,242.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Michael R. Megna sold 9,659 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $21.45, for a total transaction of $207,185.55. Following the completion of the transaction, the chief accounting officer now owns 17,588 shares of the company’s stock, valued at $377,262.60. The disclosure for this sale can be found here. Insiders sold a total of 33,109 shares of company stock valued at $709,929 in the last ninety days. 54.23% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

A number of large investors have recently made changes to their positions in KNSA. China Universal Asset Management Co. Ltd. boosted its stake in Kiniksa Pharmaceuticals by 349.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,097 shares of the company’s stock worth $72,000 after purchasing an additional 3,186 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Kiniksa Pharmaceuticals by 59.9% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 256,932 shares of the company’s stock worth $4,463,000 after purchasing an additional 96,288 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in Kiniksa Pharmaceuticals in the 3rd quarter worth approximately $777,000. Linden Thomas Advisory Services LLC boosted its stake in Kiniksa Pharmaceuticals by 100.0% during the third quarter. Linden Thomas Advisory Services LLC now owns 115,891 shares of the company’s stock valued at $2,013,000 after buying an additional 57,942 shares during the period. Finally, Alps Advisors Inc. grew its position in Kiniksa Pharmaceuticals by 38.3% during the third quarter. Alps Advisors Inc. now owns 71,103 shares of the company’s stock worth $1,235,000 after buying an additional 19,709 shares in the last quarter. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.